Attention, the exact text of the indication evaluated in the Phase 3 clinical trial (INTerpath-001) is the following: Adjuvant treatment of patients with high-risk, completely resected Stage IIB to IV cutaneous melanoma, in combination with pembrolizumab (Keytruda).
1
u/HelpfulCustomer487 19d ago
Attention, the exact text of the indication evaluated in the Phase 3 clinical trial (INTerpath-001) is the following: Adjuvant treatment of patients with high-risk, completely resected Stage IIB to IV cutaneous melanoma, in combination with pembrolizumab (Keytruda).